17:52:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss.

Kalender

2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017
2021-11-29 16:22:43
Moss, 29 November 2021

Reference is made to the annual general meeting held on 4 May 2021 where a
resolution to grant an authorisation for a share issue in connection with an
employee share purchase program (ESPP) was resolved.

Gentian Diagnostics ASA is pleased to announce that it has decided to conduct a
share issue towards company employees that has applied for shares in the ESPP.
Under the terms of the ESPP, all employees have been given the opportunity to
apply for shares up to a maximum amount of NOK 30,000. The company has decided
to award a 25% discount to the volume weighted average price between 19 November
and 26 November 2021, resulting in a subscription price of NOK 54.49 per share.
More than 50% of the employees have applied for shares for approximately NOK
570,000. Based on the application for shares by the employees, the board has
today resolved to increase the company's share capital by minimum NOK 0.10 and
maximum NOK 1046.10 by issuing minimum 1 and maximum 10,461 new shares at a
subscription price of 54.49 per shares. The shares will be subscribed for within
10 December 2021.

For further information, please contact:

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525
This information is subject to the disclosure requirements pursuant Oslo Børs
Rule Book II